Key result
Olezarsen shows no significant difference vs. volanesorsen in triglyceride reduction or pancreatitis risk.
Why the study?
Apolipoprotein C-III inhibitors have emerged as targeted treatments for familial chylomicronemia syndrome, but head-to-head evidence comparing olezarsen and volanesorsen is unavailable.
Does olezarsen 80 mg Q4W improve lipid parameters and reduce pancreatitis risk compared to volanesorsen 300 mg QW in patients with familial chylomicronemia syndrome?
Does olezarsen 80 mg Q4W improve lipid parameters and reduce pancreatitis risk compared to volanesorsen 300 mg QW in patients with familial chylomicronemia syndrome?
In this matching-adjusted indirect comparison, olezarsen and volanesorsen demonstrated comparable efficacy in lowering triglycerides and comparable safety profiles in patients with familial chylomicronemia syndrome, though power was limited by the small size of the available trials.
No significant differences seen in indirect comparison; leaves open direct randomized trials in familial chylomicronemia syndrome.
Background: Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia causing recurrent acute pancreatitis (AP). Since FCS is a genetic deficiency in functional lipoprotein lipase, conventional triglyceride-lowering therapies are ineffective in this metabolic disorder. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen and olezarsen, have emerged as targeted treatments for FCS. Aim: To compare the efficacy and safety of olezarsen 80 mg every four weeks (Q4W) versus volanesorsen 300 mg weekly (QW) in patients with FCS using an anchored matching-adjusted indirect comparison. Materials & methods: Individual patient data from the Balance trial of olezarsen (n = 45) were weighted to match baseline characteristics reported in the APPROACH trial of volanesorsen (n = 66). Outcomes included percent change in fasting triglycerides (TG) and apoC-III at 26 and 52 weeks, and risks of AP events and adverse events at 52 weeks. Results: At 52 weeks, mean differences in fasting TG and apoC-III were -27.4% (95% CI: -69.4, 14.5) and -21.3% (95% CI: -61.9, 19.3). Relative risks of AP, treatment-emergent adverse events, and serious adverse events were 0.23 (95% CI: 0.01, 5.02), 0.87 (95% CI: 0.66, 1.13) and 0.50 (95% CI: 0.08, 3.26) at week 52. The rate ratio for AP events per patient-year was 0.06 (95% CI: 0.003, 1.41). No comparisons were statistically significant. Conclusion: In this matching-adjusted indirect comparison, no statistically significant differences in outcomes were observed between olezarsen and volanesorsen in patients with FCS. These findings provide important comparative context in a setting where head-to-head evidence is unavailable.
No takes yet. Share an insight, caveat, or question.
Soran et al. (2026) studied Familial chylomicronemia syndrome (FCS) (n=111). Olezarsen vs. Volanesorsen 300 mg weekly (QW) was evaluated on Mean difference in percent change in fasting triglycerides at 52 weeks (MD -27.4%, 95% CI -69.4, 14.5). Olezarsen 80 mg every four weeks showed no statistically significant differences in 52-week fasting triglycerides (MD -27.4%) or acute pancreatitis risk compared to volanesorsen 300 mg weekly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: